Transgene and NEC Demonstrate High Accuracy of AI-based Neoantigen Prediction for the Design of Individualized Cancer Vaccine TG4050
- TG4050 is being evaluated in two Phase 1 clinical trials. It combines Transgene's proprietary myvac platform with NEC's cutting-edge Artificial Intelligence (AI) capabilities to select patient-specific neoantigens
- Data confirm that the prediction algorithm successfully identifies immunogenic cancer mutations, even among a large set of candidate mutations
- Data will be presented at upcoming Virtual AACR 2020 Session II
TOKYO, May 15, 2020 - (JCN Newswire) - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation (TSE: 6701), a leader in IT and network technologies, today announce that they will present data demonstrating that the prediction algorithm used to customize TG4050 for each patient is accurate at identifying immunogenic cancer mutations even among a large set of candidate mutations. These data were jointly generated by the Transgene, NEC and NEC Laboratories Europe GmbH teams and will be presented at the upcoming meeting of the American Association for Cancer Research (AACR) Annual Meeting 2020 (AACR Virtual Annual Meeting II).
TG4050 is an individualized therapeutic vaccine based on Transgene's myvac technology. It is powered by NEC's cutting-edge AI capabilities. Two Phase 1 trials with TG4050 are ongoing in Europe and in the USA.
TG4050 has been designed to target up to 30 patient-specific neoantigens (cancer cell mutations) which are selected using NEC's Neoantigen Prediction System, an advanced AI technology that has already been applied in the field of oncology. The prediction system is based on more than two decades of expertise in AI and has been trained on proprietary immune data, allowing it to accurately prioritize and select the most immunogenic sequences.
To evaluate the accuracy of the prediction, samples from cancer patients were collected. Healthy and tumor tissue were sequenced, and mutations were identified and ranked using the algorithm. These were then evaluated by measuring the frequency of T cells against the predicted antigens. Although preliminary, the results generated to-date suggest that the system can identify rare immunogenic mutation among a large list of candidates identified in the patients.
Transgene uses its expertise in viral vectorization to incorporate the selected neoantigen sequences in the genome of the Modified Vaccinia virus Ankara (MVA) viral vector. The Company has set up a unique in-house good manufacturing practice (GMP) unit dedicated to manufacturing the individualized batches of TG4050 needed for the clinical development of this novel individualized therapeutic vaccine.
Title of the poster: Performance of neoantigen prediction for the design of TG4050, a patient specific neoantigen cancer vaccine
Authors: Brandon Malone, Caroline Tosch, Benoit Grellier, Kousuke Onoue, Timo Sztyler, Karola Rittner, Yoshiko Yamashita, Eric Quemeneur, Kaidre Bendjama
Session Date and Time: June 22-24, 2020
Abstract/Poster Number: 4566
The abstract can be downloaded on the AACR website.
TG4050 is an individualized immunotherapy being developed for solid tumors that is based on Transgene's myvac technology and powered by NEC's longstanding artificial intelligence (AI) expertise. This virus-based therapeutic vaccine encodes neoantigens (patient-specific mutations) identified and selected by NEC's Neoantigen Prediction System. The prediction system is based on more than two decades of expertise in AI and has been trained on proprietary data allowing it to accurately prioritize and select the most immunogenic sequences.
TG4050 is designed to stimulate the immune system of patients in order to induce a T-cell response that is able to recognize and destroy tumor cells based on their own neoantigens. This individualized immunotherapy is developed for each patient and can be produced in a very short time frame.
This best-in-class candidate is being evaluated in two Phase 1 clinical trials for patients with ovarian cancers (NCT03839524) and HPV-negative head and neck cancers (NCT04183166).
myvac is a viral vector (MVA) based, individualized immunotherapy platform that has been developed by Transgene to target solid tumors. myvac-derived products are designed to stimulate the patient's immune system to recognize and destroy tumors using the patient's own cancer-specific genetic mutations. Transgene has set up an innovative network to support the development of myvac individualized immunotherapies that combines bioengineering, digital transformation, established vectorization know-how and unique manufacturing capabilities. Transgene has been awarded an "Investment for the Future" funding from Bpifrance for the development of its platform myvac. TG4050, the first myvac-derived product, is currently being evaluated in two solid tumor clinical trials.
About NEC's Neoantigen Prediction System
NEC's neoantigen prediction utilizes its proprietary artificial intelligence (AI), such as graph-based relational learning, which is combined with other sources of data to discover candidate neoantigen targets. NEC comprehensively evaluates the candidate neoantigens, with a primary focus placed on its in-house major histocompatibility complex (MHC) binding affinity prediction trained on public and proprietary datasets. These allow NEC to effectively prioritize the numerous candidate neoantigens identified in a single patient.
Transgene (Euronext: TNG) is a publicly traded French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.
The Company's clinical-stage programs consist of two therapeutic vaccines (TG4001 for the treatment of HPV-positive cancers, and TG4050, the first individualized therapeutic vaccine based on the myvac platform) as well as two oncolytic viruses (TG6002 for the treatment of solid tumors, and BT-001, the first oncolytic virus based on the Invir.IO platform).
With Transgene's myvac platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac approach allows the generation of virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.
With its proprietary platform Invir.IO, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses. Transgene has an ongoing Invir.IO collaboration with AstraZeneca.
Additional information about Transgene is available at: https://www.transgene.fr/.
Follow us on Twitter: @TransgeneSA
About NEC Corporation
NEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of "Orchestrating a brighter world." NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at https://www.nec.com.For additional information, please also visit NEC Laboratories Europe GmbH at: http://www.neclab.eu
About NEC Corporation
NEC Corporation is a leader in the integration of IT and network technologies that benefit businesses and people around the world. The NEC Group globally provides "Solutions for Society" that promote the safety, security, efficiency, and equality of society. Under the company's corporate message of "Orchestrating a brighter world," NEC aims to help solve a wide range of challenging issues and to create new social value for the changing world of tomorrow. For more information, visit NEC at https://www.nec.com.
Source: NEC Corporation
Sectors: BioTech, AI
Copyright ©2020 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Press Release
More Latest Release >>
TOYOTA GAZOO Racing to Make Virtual Le Mans Debut
Jun 05, 2020 17:34 JST
Toyota Mobility Foundation to Expand Provision of Connected and Sanitized Mobility Services to support Healthcare in Indonesia in Support of the Fight against COVID-19
Jun 05, 2020 17:22 JST
Six Companies Establish R&D Joint Venture for Commercial Vehicle Fuel Cell Systems for the Creation of a Hydrogen-based Society in China
Jun 05, 2020 17:01 JST
Singapore's LABMED shipped over 20 million masks to meet global demand
Jun 04, 2020 22:00 JST
Eisai: Brain Performance (Brain-Health) Self-Check Tool "NouKNOW" to be Used in Beauty Salons
Jun 04, 2020 11:43 JST
NEC's Netcracker 2020 Puts Service Providers at the Center of the Digital Economy
Jun 04, 2020 09:15 JST
Rakuten Mobile and NEC Agree to Jointly Develop Containerized Standalone 5G Core Network
Jun 03, 2020 10:34 JST
The Toyota Mobility Foundation and Partners Establish Digital Platform to Help Support People and Industry in Rural Germany
Jun 03, 2020 09:05 JST
Mitsubishi Corporation and NTT complete investment in HERE Technologies
Jun 02, 2020 14:54 JST
Toyota Announces its Line-up for the New GR Yaris in Japan
Jun 02, 2020 13:35 JST
Eisai Launches New Insomnia Drug Dayvigo (Lemborexant) CIV in the United States as a Treatment Option for Adults With Insomnia
Jun 02, 2020 11:05 JST
MHI RJ Aviation Group Launches as Mitsubishi Heavy Industries Ltd. Closes Acquisition of CRJ Series Program From Bombardier Inc.
Jun 02, 2020 10:23 JST
LEXUS previews the New IS
Jun 02, 2020 09:12 JST
DENSO and Certhon Establish DENSO AgriTech Solutions
Jun 01, 2020 12:48 JST
Fujitsu Signs Partnership Agreement with Scaled Agile, Inc., Driving Large-Scale Agile for Digital Transformation
Jun 01, 2020 12:01 JST
AbbVie and Eisai Announce an Approval for Partial Changes in the Marketing Approval of HUMIRA, a Fully Human Anti-TNFalpha Monoclonal Antibody
May 29, 2020 15:54 JST
Sharp Releases Notice of Corporate Spin-Off of the Display Device Business Division
May 29, 2020 15:47 JST
DENSO Announces Changes in the Areas of Responsibility of Senior Executive Officers and Executive Officers
May 29, 2020 12:05 JST
Eisai: Results from LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Trials
May 29, 2020 11:31 JST
Hitachi Announces Change in the Effective Date for Company Split and Closing Date of Share Transfer
May 28, 2020 19:18 JST